XML 59 R47.htm IDEA: XBRL DOCUMENT v3.10.0.1
License agreements - Agenus (Details)
$ / shares in Units, $ in Thousands, shares in Millions
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Feb. 14, 2017
USD ($)
$ / shares
Feb. 01, 2017
USD ($)
$ / shares
shares
Feb. 28, 2017
USD ($)
Nov. 30, 2015
item
Feb. 28, 2015
Jan. 31, 2015
item
Jun. 30, 2018
USD ($)
Mar. 31, 2018
USD ($)
Jun. 30, 2017
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Dec. 31, 2017
USD ($)
License agreements                        
Long term investment             $ 131,330     $ 131,330   $ 134,356 [1]
Research and development expense             298,089   $ 201,786 601,192 $ 609,706  
Unrealized (gain) loss on long term investments             (34,641)   (19,574) (11,962) (25,388)  
Cash and cash equivalents             928,517     $ 928,517   899,509 [1]
Agenus                        
License agreements                        
Number of program targets | item       3   4            
Royalty payments on future global net sales (as a percent)                   15.00%    
Period of notice for termination of license agreement     12 months                  
Agenus | Development, Regulatory and Commercialization Milestones | Minimum                        
License agreements                        
Royalty payments on future global net sales (as a percent)                   6.00%    
Agenus | Development, Regulatory and Commercialization Milestones | Maximum                        
License agreements                        
Royalty payments on future global net sales (as a percent)                   12.00%    
Additional milestone payments under the license agreement     $ 510,000                  
Agenus | Development Milestones                        
License agreements                        
Upfront payment under license agreement                       20,000
Additional milestone payments under the license agreement             5,000     $ 5,000    
Agenus                        
License agreements                        
Long term investment             40,300     40,300   57,900
Research and development expense             $ 900   11,200 $ 2,800 18,900  
Shares owned following stock purchase (as a percent)     11.00%   9.00%              
Ownership percentage (as a percent)             17.00%     17.00%    
Unrealized (gain) loss on long term investments             $ (43,300)   4,400 $ (17,600) (3,300)  
Total revenues               $ 1,600        
Net income (loss)               54,300        
Cash and cash equivalents               52,300        
Operating expenses               $ 43,400        
Agenus | Accrued and other liabilities                        
License agreements                        
Accrued and other liabilities             $ 900     $ 900   $ 3,200
Agenus | Stock purchase agreement                        
License agreements                        
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares   10.0                    
Purchase price of common stock   $ 60,000                    
Per share price | $ / shares $ 4.40 $ 6.00                    
Discount for lack of marketability $ 4,500                      
Fair value of shares on the issuance date 39,500                      
Total consideration paid $ 60,000                      
Long term investment                 $ 39,500   39,500  
Research and development expense                     $ 20,500  
[1] The condensed consolidated balance sheet at December 31, 2017 has been derived from the audited financial statements at that date.